De novo enthesitis in patients without enthesitis at baseline
enthesitis
ENTHESITIS
For patients without enthesitis (LEI = 0 and SPARCC = 0) at baseline, ≤ 6.4% and ≤ 15.6% of patients receiving tofacitinib or placebo developed enthesitis across locations (LEI and SPARCC) at months 1 and 3, respectively (Fig. De novo enthesitis development (patients with LEI = 0 and SPARCC = 0 at baseline). The dashed line indicates < 14% of patients without enthesitis (LEI = 0 and SPARCC = 0) at baseline with enthesitis at month 6. At months 1 and 3, the proportions of patients without enthesitis at baseline who developed de novo enthesitis were similar with tofacitinib and placebo, regardless of enthesitis location (LEI and SPARCC; Fig. 